Is NCT07578571 recruiting in Irving, TX?

Yes, NCT07578571 is currently recruiting participants at its Irving, TX location. This colorectal cancer clinical trial is actively enrolling qualified participants.

How do I join the colorectal cancer clinical trial in Irving?

To join this clinical trial in Irving, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Irving clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Colorectal Cancer Clinical Trial in Irving, TX

About This Colorectal Cancer Study in Irving

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.

Sponsor: Immunome, Inc.

Who Can Participate

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:

CRC, all subtypes

Non-squamous cell carcinoma subtypes, such as adenocarcinoma

Squamous cell carcinoma subtype

Breast cancer (subtypes based on estrogen/progesterone receptor and HER2 testing according to American Society of Clinical Oncology - College of American Pathologists guidelines):

Triple-negative breast cancer

HR+, HER2- subtype

Esophageal, esophagogastric junction, and gastric cancer:

Adenocarcinoma subtype

Other histologies, if approved by the Medical Monitor, which may include: head and neck squamous cell carcinoma; cervical cancer; bladder cancer; squamous cell carcinoma subtype of esophageal, esophagogastric junction, and gastric cancer; HER2+ breast cancer

Part B Cohorts - Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:

Cohort B1: CRC, all subtypes

Cohort B2: NSCLC

Non-squamous cell carcinoma subtypes, such as adenocarcinoma

Squamous cell carcinoma subtype

Cohorts B3 and B4: Cohort-specific disease indications may include those listed for Part A

Participants must have disease that is considered to be noncurative and meet the appropriate criteria below:

Part A only: Participants have progressed on, were intolerant to, or have a contraindication to prior SOC treatments, with no satisfactory SOC treatment options available.

Part B only:

Cohort B1 (CRC):

Participants must have previously progressed on, were intolerant to, or have a contraindication to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, bevacizumab, and for those with RAS wild-type tumors, an anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibody in advanced disease setting.

Participants with actionable biomarkers must have been treated with at least one prior appropriate biomarker-directed therapy.

If any of these therapies was given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.

Cohort B2 (NSCLC):

Participants must have previously progressed on, were intolerant to, or have a contraindication to platinum-based chemotherapy and a programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibody (given concurrently or sequentially with chemotherapy) in advanced disease setting.

Participants with actionable biomarkers must have been treated with at least one prior appropriate targeted therapy.

If any of these therapies was given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.

Cohorts B3 and B4: Criteria will be specified based on the disease indications selected.

Participants must have measurable disease as defined per RECIST v1.1

Exclusion Criteria

Previously treated with an antibody-drug conjugate (ADC) with a topoisomerase-1 (TOP1) inhibitor payload. Exception: Participants with NSCLC or breast cancer may have received up to one prior ADC with a TOP1 inhibitor payload

History of anaphylactic reaction to TOP1 inhibitors (e.g., irinotecan) or TOP1 inhibiting ADCs

Life expectancy \< 12 weeks

Prior solid organ transplant

Symptomatic ascites or pleural effusion

Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

Known history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of recurrence for at least 2 years and approved by the Medical Monitor

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Irving?

Yes, this clinical trial (NCT07578571) has an active research site in Irving, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colorectal Cancer Treatment Options in Irving, TX

If you're searching for colorectal cancer treatment options in Irving, TX, this clinical trial (NCT07578571) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Irving research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colorectal cancer clinical trials near you to find additional studies recruiting in your area.

Colorectal Cancer Clinical Trial in Irving, TX

Expert Care in Irving

IRB Approved

No-Cost Care

Apply for This Irving Location

Why Participate?

Simple Process